Anne Escande

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis

Capucine Baldini, Anne Escande, Olivier Bouché et al. · Pancreatology · 2016 · 39 citations

Surgical Oncology, Pancreatic Cancer, Elderly Patients +11

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating <i>ESR1</i> mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Thomas Bachelot et al. · Cancer Research · 2022 · 31 citations

Breast Oncology, Oncology, Esr1 Mutation +14

Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment

Philippe Barthélémy, Constance Thibault, Aude Fléchon et al. · European Urology Oncology · 2024 · 25 citations · Full text

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz et al. · European Journal of Cancer · 2020 · 17 citations

Pancreatic Cancer, Gastrointestinal Oncology, Cancérologie Digestive-prodige 37 +9